Article Text

PDF
Response to: ‘Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab’ by Eric Morand et al
  1. David Isenberg
  1. Centre for Rheumatology Research, Division of Medicine, UCL, London WC1E 6BT, UK
  1. Correspondence to Professor David Isenberg, Centre for Rheumatology Research, Division of Medicine, UCL, London WC1E 6BT, UK; d.isenberg{at}ucl.ac.uk

Statistics from Altmetric.com

I read with great interest the paper by Eric Morand and colleagues1 reporting on the utility of the Lupus Low Disease Activity State attainment using a useful form of discrimination in the phase IIb MUSE …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles